Mouse Anti-Human VEGFR-3/FLT-4
Slide this table
|Reconstitution||Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.|
|Stability and Storage||The lyophilized antibody is stable at room temperature for up to 1 month. The reconstituted antibody is stable for at least two weeks at 2-8 °C. Frozen aliquots are stable for at least 6 months when stored at -20 °C.|
|Preparation||This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified recombinant human Vascular Endothelial Growth Factor Receptor 3 (recombinant human VEGFR-3/FLT-4) extracellular domain.|
|Antigen||recombinant human soluble VEGFR-3/FLT-4|
|Application||ELISA, WB, IHC|
|Synonyms||vascular endothelial growth factor receptor-3; FLT4; PCL; LMPH1A; VEGFR3; fms-related tyrosine kinase 4|
|Description||VEGFR-1 (Flt-1), VEGFR-2 (KDR/Flk 1) and VEGFR-3 (FLT-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domains and kinase insert domains in their intracellular regions. The expression of VEGFR-1 to -3 is almost exclusively restricted to hematopoietic precursor cells, vascular and lymphatic endothelial cells and to the monocyte/macrophage lineage. These receptors play essential roles in vasculogenesis, hematopoiesis, angiogenesis and lymphangiogenesis. The VEGFR-3 cDNA encodes a 1298 amino acid (aa) residue precursor protein with a 24 aa residue signal peptide. Mature VEGFR-3 is composed of a 751 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 482 aa residue cytoplasmic domain. Both VEGF-C and VEGF-D have been shown to bind and activate VEGF R3 (Flt-4). The Flt-4 gene is widely expressed in the early embryo but becomes restricted to the lymphatic endothelial a latter stage of development. It is important for lymphangiogenesis.|
- Molecular and Cellular Effects of In Vitro Shockwave Treatment on Lymphatic Endothelial Cells. S. Rohringer et al., PLoS One. 2014; 9(12): e114806.
- Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. D. Tvorogov et al., Cancer Cell. 2010 Dec 14;18(6):630-40.
- Similarities and differences of human and experimental mouse lymphangiomas. Kasten P. et al., Dev Dyn. 2007 Oct;236(10):2952-61.
All prices plus VAT + possible delivery charges